key: cord-0758255-shc2m4o9
authors: Bardsiri, Mahla Sattarzadeh; Kouhbananinejad, Seyedeh Mehrnaz; Vahidi, Reza; Soleimany, Saeed; Moghadari, Masoud; Derakhshani, Ali; Kashani, Bahareh; Farsinejad, Alireza
title: Ubiquitous Convalescent Plasma: An Artificial Universal Plasma for COVID-19 Patients
date: 2021-06-10
journal: Transfus Apher Sci
DOI: 10.1016/j.transci.2021.103188
sha: c7d3c76b8aebbf0af75b2b4561b706813b9f83b5
doc_id: 758255
cord_uid: shc2m4o9

OBJECTIVES AND BACKGROUND: In December 2019, the first case of COVID-19 was reported in Wuhan, China. Its causative virus, is a novel strain of RNA viruses with high mortality rate. There is no definitive treatment, but among available approaches the use of recovered patients’ plasma containing specific antibodies can enhance the immune response against coronavirus. However, the dearth of eligible donors and also ABO incompatibility in plasma transfusion, have limited this therapeutic method. Therefore, it is highly desirable to introduce a simple procedure that allows efficient reduction or even removal of natural ABO antibodies. Accordingly, we aimed to evaluate a RBC-mediated adsorption technique that reduces the titer of the mentioned antibodies in plasma. METHODS/MATERIALS: This experimental study was conducted in Kerman University of Medical Sciences, Kerman, Iran. The pre- and post-incubation antibody titers of 168 plasma samples were determined. For incubation, each plasma sample was exposed (60 minutes) to different percentages of RBCs at room temperature or 4 °C. RESULTS: The results evidenced that both the concentration of RBCs and temperature had significant decreasing effects on antibody titer (P < 0.001) and all concentrations significantly reduced titer. Compared to RT, 4 °C further reduced the antibody titer. Overall, the best incubation condition for reducing antibody titer in all blood groups was 4 °C and 2% RBCs concentration. CONCLUSION: The presented adsorption procedure is able to produce universal plasma (we call it Ubiquitous Convalescent Plasma) with a non-immunogenic level of ABO mismatch antibodies which can be used for COVID-19 patients with any type of blood group with desirable simplicity, feasibility, and efficacy.

Coronavirus disease 2019 (COVID- 19) , which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in late December 2019 in Wuhan, China and rapidly spread worldwide [1, 2] . Until December 2020, the COVID-19 pandemic infected 82 million people and caused nearly 1.79 million deaths [3] . The exponentially increasing rate of cases infected with COVID-19 has prompted researchers to seek effective and definitive therapeutic options. Besides pharmacotherapy [4, 5] , other remedies such as convalescent plasma (CP) therapy, vaccination, and stem cell therapy are under investigation in several clinical trials [1, 6] . Nowadays, CP therapy is considered a safe, effective, and FDA-approved immunotherapy approach [7] which is utilized for different diseases such as SARS, Middle East respiratory syndrome coronavirus, Ebola, Zika, and pandemic influenza A [1, 8, 9] . In this therapeutic option, recovered patients' plasma containing pathogen-specific antibodies are J o u r n a l P r e -p r o o f 3 used to provide immediate immunity [1, 5, 8] . Although this approach can be effective in the COVID-19 patients [10] , it has some limitations including the dearth of eligible recovered patients and ABO-incompatibility. Except for individuals with AB blood group (universal plasma donors) [11] , others have cold reactive natural antibodies directed against red blood cells (RBCs), high concentration (≥1:64) of which leads to various complications and symptoms [12] . Despite the mentioned practical advantage of the AB group, low prevalence limits its widespread application for CP therapy; the frequency of blood groups is race/ethnicity-dependent, but overall, their prevalence in white populations is as follows:

O>A>B>AB (45%, 40%, 11%, and 4%, respectively) [13] . Therefore, it is critical to find methods that allow transfusion of ABO-mismatched plasma. Accordingly, for the first time, we decided to optimize an adsorption method to produce a universal plasma that can be transfused into patients with any blood group. By obviating the deficiency of matched donors, this process allows the widespread use of CP therapy in the treatment of various diseases such as COVID-19.

J o u r n a l P r e -p r o o f

The current study was approved by the ethical review committee affiliated with Kerman University of Medical Sciences, Kerman, Iran. Before blood collection, informed consent was obtained from 168 healthy donors (56 samples from each A, B, and O blood group; 7 samples for each incubation condition). In a sterile condition, whole blood was collected into bags containing an FDA-approved anticoagulant preservative solution (Citrate-Phosphate-Dextrose-Adenine). The ABO group, Rh type, and anti-viral antibodies (anti-hepatitis C virus and anti-human immunodeficiency virus 1/2 antibodies) were determined for each donor.

Using differential centrifugation, plasma was separated from whole blood and platelets, then stored at -20°C.

Based on the type of plasma and packed cells, for initial titration, the samples were divided were assigned for serial dilution and 500 µL of saline was transferred to tubes 2-10. After the addition of 500 µL plasma to tubes 1 and 2, tube 2 was mixed thoroughly and 500 µL of its content was transferred into the next tube. This process was repeated for the next tubes and eventually, 500 µL of contents of tube 10 was removed. Therefore, tubes 1-10 contained undiluted plasma and dilutions of 1/2, 1/4, 1/8, 1/16, 1/32, 1/64, 1/128, 1/256, and 1/512 of plasma, respectively. Finally, 10 µL of related packed RBCs was transferred into each tube (final concentration=2%) and after centrifugation (1000×g/30s), agglutination was examined macroscopically. The last serum dilution with visible agglutination was defined as the antibody titer [14] .

According to the packed red cell concentrations (0.5, 1, 2, and 4%) and incubation temperature minutes at RT or 4°C. The mixture was shaken during the incubation phase periodically and then centrifuged at 1000 ×g for 5 minutes to form tightly-packed cells. Finally, the supernatant was harvested for the secondary antibody titration according to section 2.2. procedure.

Statistical analysis was performed using the IBM SPSS Statistics 23 software. Reciprocal antibody titers were transformed into log2 (x+1) prior to analysis [15, 16] . The comparisons of antibody titer reduction in different temperatures and RBC concentrations were performed by two-way analysis of covariance (ANCOVA). The initial titer was used as the concomitant covariate in ANCOVA analysis for adjustment. The initial assumptions of ANCOVA analysis (normality and homogeneity of regression slopes) were also checked. The level of significance was considered P<0.05. Results were presented as mean±standard error (SE).

Overall, the concentration of RBC and incubation temperature had significant decreasing effects on antibody titer (P<0.001). However, the interaction between the concentration of 

There is no specific approved protocol for the treatment of COVID-19, but some antiviral drugs and adjunctive therapies (use of blood products and immunomodulators) can be applied for the alleviation of coronavirus inflammatory effects [17, 18] . For instance, stem cells with immunomodulatory properties as well as CP can be added to the treatment protocols of COVID-19 [19] . Donated plasma from recovered patients has been investigated in the treatment of many infectious diseases such as H1N1 influenza, SARS, and Ebola [20] . This blood product is cost-effective and provides passive immunization by virus-specific antibodies, limits virus replication, and accelerates immune response to viral infection [21, 22] . Recently, this modality has been noticed as promising supportive treatment for COVID-19 patients and its proper usage at an early stage of the disease can reduce hospitalization [23] . In this regard, increased the pao2/fio2 ratio and neutralizing antibody titer from 40-60 to 80-320 [2] . In addition, available findings from other experiments revealed that CP therapy along with recommended drug protocols could be considered as a safe and effective method for disease improvement and mortality reduction [24, 25] . However, ABO-matched donor availability from COVID-19-recovered patients is a challenging issue since incompatible plasma transfusion is associated with some antibody-related adverse complications such as acute hemolytic transfusion reactions (AHTRs), allergic reactions, transfusion-related acute lung injury (TRALI), and febrile non-hemolytic transfusion reactions (FNHTRs) [26] . These problematic antibodies can be removed by attaching to specific antigens of RBCs through the adsorption process. For instance, Das and colleagues performed polyethylene glycol (PEG) and low ionic strength saline (LISS)-papain adsorption methods in warm autoimmune hemolytic anemia patients to remove the corresponding autoantibodies. They reported that the PEG method is a more efficient autoadsorption technique for complete autoantibody elimination [27] .

Concerning COVID-19, theoretically, by reducing the titer of ABO-antibodies the final plasma J o u r n a l P r e -p r o o f will contain a non-immunogenic level of these antibodies (<1:64) while preserving the coronavirus-specific antibodies.

One of the effective factors in the adsorption procedure is the antibody, which its reaction with antigen depends on different elements such as temperature, antigen concentration, plasma/cell ratio, pH, and incubation time [28] . ABO natural antibodies (cold agglutinins, CA) are mainly IgM and the optimum temperature for their reaction is 0-4°C. The temperature range of cold agglutinin reaction with antigen is known as thermal amplitude and determines the pathogenicity of CA. Because these antibodies can also react at >4°C, two temperatures (RT and 4°C) were selected in the present study [29] . Furthermore, since the use of a high concentration of antigen for antibody neutralization may cause plasma contamination during the adsorption process, different RBC concentrations (0.5, 1, 2, and 4%) were investigated to obtain the lowest concentration that provides an acceptable reduction in the antibody titer.

According to our results, 4°C had a significantly higher decreasing effect on antibody titer compared to RT. The linear form of the graph in Figure 1 indicates that the antibody titer decreases with increasing RBCs concentration. The lowest concentration of RBCs which declined the antibody titer to an acceptable level (<1:64) was 2 percent, and although concentrations >2% caused more titer diminution, these reductions may be associated with potential RBCs-related contamination of the final plasma. Therefore, we selected 2% as an optimum RBC concentration. Overall, the best incubation condition for reducing antibody titer in all blood groups was 4°C and 2% RBCs concentration.

Despite the promising results of the present study, the effectiveness of this product in clinical trials has not been evaluated. In addition, ensuring the accuracy of the results requires further studies with larger sample sizes.

In conclusion, our modified adsorption procedure is able to produce universal plasma (we call it Ubiquitous Convalescent Plasma) with a non-immunogenic level of ABO mismatch antibodies which can be used for different infectious diseases such as COVID-19 patients with any type of blood group with desirable simplicity, feasibility, and efficacy. 

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

World Health Organization. Coronavirus disease (COVID-19) pandemic

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?

Mesenchymal stem cells and management of COVID-19 pneumonia

Another Achievement in Administration's

Convalescent plasma: a valid option in the treatment of COVID-19

Pivotal role of convalescent plasma in managing emerging infectious diseases

Convalescent plasma as a potential therapy for COVID-19

Are there any alternatives for transfusion of AB plasma as universal donor in an emergency release setting?

Brecher ME editor. AABB Technical Manual 15th Ed

Distribution of ABO blood groups and rhesus factor in a Large Scale Study of different cities and ethnicities in Khuzestan province

Antibody Identification, and Serologic Compatibility Testing

Proposed method for agglutinating antibody titer analysis and its use as indicator of acquired immunity in pacu, Piaractus mesopotamicus

Hematology and agglutination titer after polyvalent immunization and subsequent challenge with Aeromonas hydrophila in Nile tilapia (Oreochromis niloticus)

Novel coronavirus (COVID-19): a new emerging pandemic threat

The immunology of COVID-19: is immune modulation an option for treatment?

Mesenchymal stem cell therapy for COVID-19: present or future

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

The convalescent sera option for containing COVID-19

Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients

Management of COVID-19 Virus Infection by Convalescent Plasma

Convalescent plasma transfusion for the treatment of COVID-19: Systematic review

Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea

EUA of COVID-19 convalescent plasma for the treatment of COVID-19 in hospitalized patients: fact sheet for health care providers

Utility of adsorption techniques in serological evaluation of warm autoimmune haemolytic anaemia

Factors affecting the antigen-antibody reaction

New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia